YANTAI ZHENGHAI BIOTECHNOLOGY CO., LTD. Yantai Zhenghai Biotechnology Co., Ltd. Stock
Equities
300653
CNE100002NZ1
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.75 CNY | -1.82% |
|
-3.32% | -14.71% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 480M 66.28M | Sales 2025 * | 579M 80.04M | Capitalization | 4.46B 616M |
|---|---|---|---|---|---|
| Net income 2024 * | 219M 30.26M | Net income 2025 * | 267M 36.89M | EV / Sales 2024 * | 9.29 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.69 x |
| P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
16.7
x | Employees | 332 |
| Yield 2024 * |
2.42% | Yield 2025 * |
2.91% | Free-Float | 55.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.82% | ||
| 1 week | -3.32% | ||
| Current month | +4.83% | ||
| 1 month | +10.94% | ||
| 3 months | +6.91% | ||
| 6 months | -19.01% | ||
| Current year | -14.71% |
1 week
24.48
25.49
1 month
22.0827.96
Current year
18.1129.24
1 year
18.1138.43
3 years
18.1158.83
5 years
18.1158.83
10 years
6.8858.83
| Managers | Title | Age | Since |
|---|---|---|---|
Shu Zhuang Sha
CEO | Chief Executive Officer | 44 | 16-11-17 |
Li Zhao
DFI | Director of Finance/CFO | 46 | 15-06-18 |
Mei Jiao Lu
SEC | Corporate Secretary | 42 | 15-06-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Li Xu
CHM | Chairman | 50 | 15-06-08 |
Xi Liang Song
BRD | Director/Board Member | 59 | - |
Dong Qun
BRD | Director/Board Member | 58 | 15-06-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 24.75 | -1.82% | 2 104 389 |
| 24-05-20 | 25.21 | +1.20% | 2,999,570 |
| 24-05-17 | 24.91 | +0.77% | 2,141,734 |
| 24-05-16 | 24.72 | -0.36% | 2,436,647 |
| 24-05-15 | 24.81 | -2.74% | 3,496,550 |
End-of-day quote Shenzhen S.E., May 20, 2024
More quotes
Yantai Zhenghai Bio-Tech Co Ltd is a company engaged in production and sales of implantable medical devices. The Company has two types of products which are soft tissue repair materials and hard tissue repair materials. The soft tissue repair materials include oral repair membranes, biofilms and skin repair membranes. The hard tissue repair materials include bone repair materials.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.75
CNY
Average target price
32.58
CNY
Spread / Average Target
+31.62%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.71% | 627M | |
| +10.37% | 126B | |
| -5.47% | 11.33B | |
| +4.83% | 9.27B | |
| +36.53% | 5.5B | |
| -25.10% | 4.61B | |
| +8.61% | 3.45B | |
| -10.05% | 2.81B | |
| -10.99% | 2.09B | |
| -10.20% | 2.08B |
- Stock Market
- Equities
- 300653 Stock
